共 90 条
Mechanisms of action of newer antibiotics for Gram-positive pathogens
被引:209
作者:

Hancock, REW
论文数: 0 引用数: 0
h-index: 0
机构:
Univ British Columbia, Ctr Microbial Dis & Immun Res, Vancouver, BC V6T 1Z4, Canada Univ British Columbia, Ctr Microbial Dis & Immun Res, Vancouver, BC V6T 1Z4, Canada
机构:
[1] Univ British Columbia, Ctr Microbial Dis & Immun Res, Vancouver, BC V6T 1Z4, Canada
关键词:
D O I:
10.1016/S1473-3099(05)70051-7
中图分类号:
R51 [传染病];
学科分类号:
100401 ;
摘要:
Certain Gram-positive bacteria, including meticillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, and quinolone-resistant Streptococcus pneumoniae have achieved the status of "superbugs", in that there are flew or no antibiotics available for therapy against these pathogens. Only a few classes of novel antibiotics have been introduced in the past 40 years, and all since 1999, including the streptogramin combination quinupristin/dalfopristin (Synercid), the oxazolidinone linezolid, and the lipopeptide daptomycin. This review discusses the mechanisms of antibiotic action against Gram-positive pathogens, and resistance counter-mechanisms developed by Gram-positive bacteria, with emphasis on the newer agents.
引用
收藏
页码:209 / 218
页数:10
相关论文
共 90 条
- [1] Novel antibacterial agents for the treatment of serious Gram-positive infections[J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2003, 12 (03) : 379 - 399Abbanat, D论文数: 0 引用数: 0 h-index: 0机构: Johnson & Johnson Res & Dev, Raritan, NJ 08869 USA Johnson & Johnson Res & Dev, Raritan, NJ 08869 USAMacielag, M论文数: 0 引用数: 0 h-index: 0机构: Johnson & Johnson Res & Dev, Raritan, NJ 08869 USA Johnson & Johnson Res & Dev, Raritan, NJ 08869 USABush, K论文数: 0 引用数: 0 h-index: 0机构: Johnson & Johnson Res & Dev, Raritan, NJ 08869 USA Johnson & Johnson Res & Dev, Raritan, NJ 08869 USA
- [2] Drugs of the 21st century: telithromycin (HMR 3647) - the first ketolide[J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 51 (03) : 497 - 511Ackermann, G论文数: 0 引用数: 0 h-index: 0机构: Univ Leipzig, Inst Med Microbiol & Epidemiol Infect Dis, D-04103 Leipzig, Germany Univ Leipzig, Inst Med Microbiol & Epidemiol Infect Dis, D-04103 Leipzig, GermanyRodloff, AC论文数: 0 引用数: 0 h-index: 0机构: Univ Leipzig, Inst Med Microbiol & Epidemiol Infect Dis, D-04103 Leipzig, Germany Univ Leipzig, Inst Med Microbiol & Epidemiol Infect Dis, D-04103 Leipzig, Germany
- [3] Doxycycline is a cost-effective therapy for hospitalized patients with community-acquired pneumonia[J]. ARCHIVES OF INTERNAL MEDICINE, 1999, 159 (03) : 266 - 270Ailani, RK论文数: 0 引用数: 0 h-index: 0机构: Meridia Huron Hosp, Dept Med, E Cleveland, OH 44112 USA Meridia Huron Hosp, Dept Med, E Cleveland, OH 44112 USAAgastya, G论文数: 0 引用数: 0 h-index: 0机构: Meridia Huron Hosp, Dept Med, E Cleveland, OH 44112 USA Meridia Huron Hosp, Dept Med, E Cleveland, OH 44112 USAAilani, RK论文数: 0 引用数: 0 h-index: 0机构: Meridia Huron Hosp, Dept Med, E Cleveland, OH 44112 USA Meridia Huron Hosp, Dept Med, E Cleveland, OH 44112 USAMukunda, BN论文数: 0 引用数: 0 h-index: 0机构: Meridia Huron Hosp, Dept Med, E Cleveland, OH 44112 USA Meridia Huron Hosp, Dept Med, E Cleveland, OH 44112 USAShekar, R论文数: 0 引用数: 0 h-index: 0机构: Meridia Huron Hosp, Dept Med, E Cleveland, OH 44112 USA Meridia Huron Hosp, Dept Med, E Cleveland, OH 44112 USA
- [4] DAPTOMYCIN DISRUPTS MEMBRANE-POTENTIAL IN GROWING STAPHYLOCOCCUS-AUREUS[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (11) : 2282 - 2287ALBORN, WE论文数: 0 引用数: 0 h-index: 0机构: Infectious Disease Research, Lilly Research Laboratories, Eli Lilly and Company, IndianapolisALLEN, NE论文数: 0 引用数: 0 h-index: 0机构: Infectious Disease Research, Lilly Research Laboratories, Eli Lilly and Company, IndianapolisPRESTON, DA论文数: 0 引用数: 0 h-index: 0机构: Infectious Disease Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis
- [5] Two consecutive outbreaks of Stenotrophomonas maltophilia (Xanthomonas maltophilia) in an intensive-care unit defined by restriction fragment-length polymorphism typing[J]. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 1999, 20 (08) : 553 - 556Alfieri, N论文数: 0 引用数: 0 h-index: 0机构: Calgary Dist Hosp Grp, Calgary, AB T2V 1P9, CanadaRamotar, K论文数: 0 引用数: 0 h-index: 0机构: Calgary Dist Hosp Grp, Calgary, AB T2V 1P9, CanadaArmstrong, P论文数: 0 引用数: 0 h-index: 0机构: Calgary Dist Hosp Grp, Calgary, AB T2V 1P9, CanadaSpornitz, ME论文数: 0 引用数: 0 h-index: 0机构: Calgary Dist Hosp Grp, Calgary, AB T2V 1P9, CanadaRoss, G论文数: 0 引用数: 0 h-index: 0机构: Calgary Dist Hosp Grp, Calgary, AB T2V 1P9, CanadaWinnick, J论文数: 0 引用数: 0 h-index: 0机构: Calgary Dist Hosp Grp, Calgary, AB T2V 1P9, CanadaCook, DR论文数: 0 引用数: 0 h-index: 0机构: Calgary Dist Hosp Grp, Calgary, AB T2V 1P9, Canada
- [6] Mechanism of action of oritavancin and related glycopeptide antibiotics[J]. FEMS MICROBIOLOGY REVIEWS, 2003, 26 (05) : 511 - 532Allen, NE论文数: 0 引用数: 0 h-index: 0机构: Eli Lilly & Co, Infect Dis Res, Indianapolis, IN 46285 USA Eli Lilly & Co, Infect Dis Res, Indianapolis, IN 46285 USANicas, TI论文数: 0 引用数: 0 h-index: 0机构: Eli Lilly & Co, Infect Dis Res, Indianapolis, IN 46285 USA Eli Lilly & Co, Infect Dis Res, Indianapolis, IN 46285 USA
- [7] INHIBITION OF MEMBRANE POTENTIAL-DEPENDENT AMINO-ACID-TRANSPORT BY DAPTOMYCIN[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (12) : 2639 - 2642ALLEN, NE论文数: 0 引用数: 0 h-index: 0机构: Infectious Disease Research, Lilly Research Laboratories, Eli Lilly and Company, IndianapolisALBORN, WE论文数: 0 引用数: 0 h-index: 0机构: Infectious Disease Research, Lilly Research Laboratories, Eli Lilly and Company, IndianapolisHOBBS, JN论文数: 0 引用数: 0 h-index: 0机构: Infectious Disease Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis
- [8] INHIBITION OF PEPTIDOGLYCAN BIOSYNTHESIS IN GRAM-POSITIVE BACTERIA BY LY146032[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (07) : 1093 - 1099ALLEN, NE论文数: 0 引用数: 0 h-index: 0HOBBS, JN论文数: 0 引用数: 0 h-index: 0ALBORN, WE论文数: 0 引用数: 0 h-index: 0
- [9] Oxazolidinone antibiotics target the P site on Escherichia coli ribosomes[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (04) : 1080 - 1085Aoki, H论文数: 0 引用数: 0 h-index: 0机构: Univ Toronto, Charles H Best Inst, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, CanadaKe, LZ论文数: 0 引用数: 0 h-index: 0机构: Univ Toronto, Charles H Best Inst, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, CanadaPoppe, SM论文数: 0 引用数: 0 h-index: 0机构: Univ Toronto, Charles H Best Inst, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, CanadaPoel, TJ论文数: 0 引用数: 0 h-index: 0机构: Univ Toronto, Charles H Best Inst, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, CanadaWeaver, EA论文数: 0 引用数: 0 h-index: 0机构: Univ Toronto, Charles H Best Inst, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, CanadaGadwood, RC论文数: 0 引用数: 0 h-index: 0机构: Univ Toronto, Charles H Best Inst, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, CanadaThomas, RC论文数: 0 引用数: 0 h-index: 0机构: Univ Toronto, Charles H Best Inst, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, CanadaShinabarger, DL论文数: 0 引用数: 0 h-index: 0机构: Univ Toronto, Charles H Best Inst, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, CanadaGanoza, MC论文数: 0 引用数: 0 h-index: 0机构: Univ Toronto, Charles H Best Inst, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada
- [10] Vancomycin-resistant enterococci in intensive-care hospital settings: Transmission dynamics, persistence, and the impact of infection control programs[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (12) : 6908 - 6913Austin, DJ论文数: 0 引用数: 0 h-index: 0机构: Univ Oxford, Wellcome Trust Ctr Epidemiol Infect Dis, Oxford OX1 3PS, EnglandBonten, MJM论文数: 0 引用数: 0 h-index: 0机构: Univ Oxford, Wellcome Trust Ctr Epidemiol Infect Dis, Oxford OX1 3PS, EnglandWeinstein, RA论文数: 0 引用数: 0 h-index: 0机构: Univ Oxford, Wellcome Trust Ctr Epidemiol Infect Dis, Oxford OX1 3PS, EnglandSlaughter, S论文数: 0 引用数: 0 h-index: 0机构: Univ Oxford, Wellcome Trust Ctr Epidemiol Infect Dis, Oxford OX1 3PS, EnglandAnderson, RM论文数: 0 引用数: 0 h-index: 0机构: Univ Oxford, Wellcome Trust Ctr Epidemiol Infect Dis, Oxford OX1 3PS, England